Axsome Therapeutics (AXSM) FDA Announcement summary
Event summary combining transcript, slides, and related documents.
FDA Announcement summary
9 Jul, 2026Introduction and purpose
FDA approved Symbravo (meloxicam and rizatriptan) for acute treatment of migraine with or without aura in adults, marking a significant milestone and representing a novel multi-mechanistic approach targeting multiple migraine pathways.
Symbravo aims to address unmet needs in migraine care, targeting patients dissatisfied with current acute treatments due to limited efficacy or side effects, and is designed to provide rapid, enhanced, and consistent migraine pain relief.
The approval provides a new option for the estimated 39 million migraine sufferers in the U.S.
Details of approval or decision
Symbravo is indicated for acute migraine treatment in adults, with or without aura, and is not for prevention or cluster headache.
Approval was based on pivotal phase III trials (INTERCEPT, MOMENTUM, MOVEMENT) demonstrating efficacy across mild, moderate, and severe migraine pain, covering a broad range of patient histories.
The product uses MoSEIC technology to enhance absorption of meloxicam, combined with rizatriptan, leveraging multiple mechanisms to address both inflammation and vascular dilation.
Impact on industry and stakeholders
Symbravo enters a large market with over 22 million annual prescriptions, mostly for generic triptans, and is positioned to compete in a concentrated market dominated by a few brands.
Over 80% of migraine patients discontinue current treatments within a year, highlighting dissatisfaction and opportunity for new therapies.
Market research indicates about 75% of healthcare providers are likely or extremely likely to prescribe Symbravo, citing rapid efficacy and safety.
Patient advocacy groups highlight the approval as a step forward in reducing stigma and improving access to care.
Symbravo is protected by patents extending to at least 2040.
Latest events from Axsome Therapeutics
- AUVELITY momentum and an expanded pipeline underpin the next phase of growth.AXSM
UBS Global Biopharma Conference 2026 - AUVELITY momentum and a deep pipeline frame a $260M-revenue quarter.AXSM
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 52% as AUVELITY-led sales narrowed losses and pipeline milestones advanced.AXSM
Q3 2026 - Auvelity’s launch and pipeline expansion underpin an expected next phase of growth.AXSM
H.C. Wainwright 28th Annual Global Investment Conference - AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook.AXSM
Morgan Stanley 24th Annual Global Healthcare Conference - AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth.AXSM
12th Annual Cantor Fitzgerald Global Healthcare Conference - AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials.AXSM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue grew 46% to $218.4M, led by AUVELITY's Alzheimer's launch and pipeline progress.AXSM
Q2 2026 - Late-stage CNS pipeline targets high unmet needs with strong data and major commercial potential.AXSM
R&D Day 2025